{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:25:58Z","timestamp":1790821558034,"version":"4.1.0"},"reference-count":42,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019944","name":"Sanofi-Aventis Deutschland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019944","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Neurol Disord"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p> Teriflunomide is a once-daily oral disease-modifying therapy (DMT) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Only limited information is available about its real-world use and changes over time. <\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives:<\/jats:title><jats:p> To collect real-world data on teriflunomide use in clinical routine (and comparison to the previously conducted study TAURUS-MS). <\/jats:p><\/jats:sec><jats:sec><jats:title>Design:<\/jats:title><jats:p> National, open, non-interventional, prospective, multicenter study. <\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p> TAURUS-MS II was conducted at 220 German sites between July 2017 and March 2022, including RRMS patients treated with teriflunomide. Data on patient demographics, MS history, previous treatment, therapy satisfaction, and safety were collected. <\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p> In total, 752 patients were included (65% female) with a mean age (\u00b1standard deviation) of 43\u2009\u00b1\u200911\u2009years. Sixty-six percent had DMT before, and 46% had discontinued their last pretreatment \u22646\u2009months prior to study entry. Among the latter, previous DMTs were interferon (21%), glatiramer acetate (11%), and dimethyl fumarate (9%), and reasons for discontinuation were adverse events (AEs; 55%) and insufficient efficacy (16%). Over 24\u2009months, the mean treatment Satisfaction Questionnaire for Medication scores improved by 6\u2009\u00b1\u200929 points on effectiveness, 8\u2009\u00b1\u200920 on convenience, and 12\u2009\u00b1\u200925 on global satisfaction. The mean number of MS relapses decreased from 0.81\u2009\u00b1\u20090.81 in the 24\u2009months prior to 0.27\u2009\u00b1\u20090.57 within 24\u2009months after study entry. Non-serious AEs occurred in 423 patients (56%) and serious AEs in 49 patients (7%). Most reported AEs were alanine aminotransferase increase (11%), hypertension (8%), and alopecia (7%). Compared to TAURUS-MS, patients in TAURUS-MS II were younger, had a higher employment rate, and a higher share of treatment-na\u00efve patients. <\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p> Mean number of relapses was significantly reduced. Patient satisfaction was significantly improved compared to previous DMT. Tolerability was comparable to previous trials. <\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration:<\/jats:title><jats:p> Bundesinstitut f\u00fcr Arzneimittel und Medizinprodukte public database for non-interventional studies, number 7138. <\/jats:p><\/jats:sec>","DOI":"10.1177\/17562864241252722","type":"journal-article","created":{"date-parts":[[2024,5,27]],"date-time":"2024-05-27T09:55:16Z","timestamp":1716803716000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["TAURUS-MS II: real-world use of teriflunomide in Germany and changes in treatment patterns over time"],"prefix":"10.1177","volume":"17","author":[{"given":"Boris-Alexander","family":"Kallmann","sequence":"first","affiliation":[{"name":"Kallmann Neurologie, Multiple-Sclerosis-Center Bamberg, Bamberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"zu Eulenburg","sequence":"additional","affiliation":[{"name":"Medical Affairs Neurology, Sanofi-Aventis Deutschland GmbH, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer S.","family":"Kullmann","sequence":"additional","affiliation":[{"name":"Medical Affairs Neurology, Sanofi-Aventis Deutschland GmbH, Industriepark H\u00f6chst, Geb. K703, Frankfurt am Main D-65926, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"M\u00e4urer","sequence":"additional","affiliation":[{"name":"Klinikum W\u00fcrzburg Mitte, Juliusspital, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2024,5,27]]},"reference":[{"key":"bibr1-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1352458520970841"},{"key":"bibr2-17562864241252722","unstructured":"Holstiege J, Steffen A, Goffrier B, et al. Epidemiologie der Multiplen Sklerose\u2013eine populationsbasierte deutschlandweite Studie. Versorgungsatlas-Bericht Nr. 17\/09, Zentralinstitut f\u00fcr die kassen\u00e4rztliche Versorgung in Deutschland, Berlin, 2017."},{"key":"bibr3-17562864241252722","unstructured":"Deutsche Gesellschaft f\u00fcr Neurologie (DGN)\/Krankheitsbezogenes Kompetenznetz Multiple Sklerose (KKNMS). Leitlinie zur Diagnose und Therapie der MS, https:\/\/www.kompetenznetz-multiplesklerose.de\/wp-content\/uploads\/2016\/02\/dgn-kknms_ms-ll_20140813.pdf (2014, accessed 5 October 2023)."},{"key":"bibr4-17562864241252722","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S61651"},{"key":"bibr5-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2010.01444.x"},{"key":"bibr6-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1014656"},{"key":"bibr7-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(13)70308-9"},{"key":"bibr8-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1352458513507821"},{"key":"bibr9-17562864241252722","unstructured":"European Medicines Agency. Aubagio (teriflunomide). European public assessment report, EMEA\/H\/C\/002514 \u2013 N\/0044, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aubagio-epar-product-information_en.pdf (2023, accessed 5 October 2023)."},{"key":"bibr10-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00364-1"},{"key":"bibr11-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-021-01157-2"},{"key":"bibr12-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250820"},{"key":"bibr13-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86347-3"},{"key":"bibr14-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-020-01882-2"},{"key":"bibr15-17562864241252722","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S254427"},{"key":"bibr16-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1756286419835077"},{"key":"bibr17-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.11.1444"},{"key":"bibr18-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1308147"},{"key":"bibr19-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-36"},{"key":"bibr20-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(95)00115-N"},{"key":"bibr21-17562864241252722","unstructured":"Data on File, Sanofi-Aventis, Germany."},{"key":"bibr22-17562864241252722","unstructured":"Hemmer B, et al. Diagnose und Therapie der Multiplen Sklerose, Neuromyelitis-optica-Spektrum-Erkrankungen und MOG-IgG-assoziierten Erkrankungen, S2k-Leitlinie. In: Deutsche Gesellschaft f\u00fcr Neurologie (ed.), Leitlinien f\u00fcr Diagnostik und Therapie in der Neurologie, 2023. www.dgn.org\/leitlinien."},{"key":"bibr23-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517751049"},{"key":"bibr24-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512450354"},{"key":"bibr25-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/17562864211005588"},{"key":"bibr26-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002441"},{"key":"bibr27-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102438"},{"key":"bibr28-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79"},{"key":"bibr29-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2015.02.005"},{"key":"bibr30-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1756285616634247"},{"key":"bibr31-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-2-12"},{"key":"bibr32-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.10.002"},{"key":"bibr33-17562864241252722","first-page":"527","volume":"18","author":"Coleman CI","year":"2012","journal-title":"J Manag Care Spec Pharm"},{"key":"bibr34-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102521"},{"key":"bibr35-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511433302"},{"key":"bibr36-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2016.12.038"},{"key":"bibr37-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1007\/s100720170025"},{"key":"bibr38-17562864241252722","unstructured":"Sanofi, Website for U.S. Health Care Professionals. AUBAGIO (teriflunomide), https:\/\/www.aubagiohcp.com\/clinical-trial-safety-data (2023, accessed 5 October 2023)."},{"key":"bibr39-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.104472"},{"key":"bibr40-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0183-3"},{"key":"bibr41-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1136\/jech.2003.008466"},{"key":"bibr42-17562864241252722","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.111.171074"}],"container-title":["Therapeutic Advances in Neurological Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864241252722","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17562864241252722","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17562864241252722","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T16:14:15Z","timestamp":1741018455000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17562864241252722"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":42,"alternative-id":["10.1177\/17562864241252722"],"URL":"https:\/\/doi.org\/10.1177\/17562864241252722","relation":{},"ISSN":["1756-2864","1756-2864"],"issn-type":[{"value":"1756-2864","type":"print"},{"value":"1756-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"article-number":"17562864241252722"}}